Twilight Litaka Pharma Limited
Regd. Office : Himalaya Estate, 16-A Shivajinagar, Pune 411 005

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2011

(Rs.in Lac)

S No.	Particulars	Quarter Ended (Unaudited)			9 Months Ended (Unaudited)		Financial Year Ended (Audited)
		31.12.2011	30.09.2011	31.12.2010	31.12.2011	31.12.2010	31.03.2011
1	a. Net Sales / Income From Operations	18672.48	18065.15	17215.24	55093.62	49502.92	65678.11
	b. Other Operating Income	-	-	-		-	-
2	Expenditure						
	a Increase/decrease in stock in trade & WIP	23.17	6.88	-49.34	-140.16	-704.89	-778.19
	b Consumption of Raw material	13515.24	12168.33	12055.98	38550.68	35295.70	46721.12
	c Purchase of traded goods.	536.95	1577.12	1210.17	3471.36	3559.38	4643.94
	d Employee cost	538.05	513.99	468.01	1529.61	1320.17	1767.93
	e Depreciation	133.48	144.80	95.69	382.57	272.98	364.87
	f Other expenditure	1240.54	1167.22	949.64	3437.22	2749.07	3806.45
	g Expenditure (a to f)	15987.43	15578.34	14730.15	47231.28	42492.41	56526.12
3	**Profit from Operations before Other Income, Interest and Exceptional Items (1-2)**	2685.05	2486.81	2485.09	7862.34	7010.51	9151.99
4	Other Income	13.88	42.12	67.37	77.49	169.97	373.26
5	**Profit before Interest & Exceptional Items (3+4)**	2698.93	2528.93	2552.46	7939.83	7180.48	9525.25
6	Interest	1283.84	1198.72	814.48	3466.17	2058.29	3187.22
7	**Profit after Interest, but before Exceptional Items (5-6)**	1415.09	1330.21	1737.98	4473.66	5122.19	6338.03
8	Exceptional Items	-	-	-		-	-
9	**Profit from Ordinary Activities before tax (7+8)**	1415.09	1330.21	1737.98	4473.66	5122.19	6338.03
10	Tax Expenses	477.00	347.00	376.00	1270.00	1081.00	1393.57
11	**Profit from Ordinary Activities after tax (9-10)**	938.09	983.21	1361.98	3203.66	4041.19	4944.46
12	Extraordinary items (net of tax expense)	-	-	-	-	-	-
13	**Net Profit for the period**	938.09	983.21	1361.98	3203.66	4041.19	4944.46
14	Paid-up Equity Share Capital (Equity share of Rs.5/- each)	1239.06	1239.06	1064.06	1239.06	1064.06	1064.06
15	Reserve excluding revaluation reserves	18837.86	17899.77	12264.31	18837.86	12264.31	12695.21
16	Earning per share (EPS)						
	a. Basic and diluted EPS before extraordinary items for the period	*3.74	*3.85	*6.40	*13.44	*18.99	*23.23
	b. Basic and diluted EPS after extraordinary items for the period.	*3.74	*3.85	*6.40	*13.44	*18.99	*23.23
17	Aggregate of non promoter shareholding						
	number of shares	23225796	22171810	12343051	23225796	12343051	12516051
	percentage of shareholding	93.72	89.47	58.00	93.72	58.00	58.81
18	Promoters and Promoters Group shareholding						
	a) Pledged / Encumbered						
	- Number of shares	1531247	2126606	8541025	1531247	8541025	8440541
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	98.44	81.50	95.56	98.44	95.56	96.29
	- Percentage of shares (as % to the total share capital of the Company)	6.18	8.58	40.13	6.18	40.13	39.66
	b) Non Encumbered						
	- Number of shares	24242	482869	397209	24242	397209	324693
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	1.56	18.50	4.44	1.56	4.44	3.71
	- Percentage of shares (as % to the total share capital of the Company)	0.10	1.95	1.87	0.10	1.87	1.53

* not annulised

Notes :

1] The above unaudited results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 11th February, 2012.

2] Provision for Tax includes Current Year Tax and Deferred Tax .

3] The Company is primarily engaged in Pharmaceutical formulations business, which in the context of Accounting Standard (AS17) "'Segment Reporting" is considered to be the only business segment.

4] Between 10th June,11 to 16th June,11 the company has alloted 35,00,000 Equity Shares of Rs.5/- each at Rs. 86/- per Equity Shares as per Terms of issue of 35,00,000 Convertible Warrants, which were listed on BSE and NSE.

5] Briocia Pharma (India) Ltd. has become 100% subsidiary of the Company w.e.f.25th November,10. The financial results for the quarter ended 31st December,2011 of the company are prepared on standalone basis.

6] The above results were subjected to Limited Review by the Statutory Auditors of the Company pursuant to Clause 41 of the Listing Agreement.

7) On receipt of NOC from the bankers of the company, the dividend which was declared in the last Annual General Meeting held on 29th September,2011 will be paid to the shareholders of the company

8] Previous year's figures have been regrouped and rearranged wherever necessary.

9] During the current quarter, eight investor complaints were received. There was no pending investor complaint at the beginning of the quarter and five investor complaints were pending at the end of the quarter

For TWILIGHT LITAKA PHARMA LIMITED

GOPAL RAMOURTI
Managing Director

TWILIGHT LITAKA PHARMA LTD. PUNE

Place : Pune
Date : 11th February, 2012